Rinvoq Warning Label Updated to Add Cancer and Heart Risks Seen With Xeljanz Side Effects
Rinvoq will now carry label warnings on cancer and heart risks which were first discovered through a study of Xeljanz side effects.
Rinvoq will now carry label warnings on cancer and heart risks which were first discovered through a study of Xeljanz side effects.
A new study announced by Eli Lilly appears to suggest Olumiant, a rheumatoid arthritis drug, does not need the same label warnings for heart problems as Xeljanz, it's competitor.
A new study suggests the risk of heart problems linked to Xeljanz is similar across all other rheumatoid arthritis drugs belonging to the same class of medications.
The eczema cream Opzelura, made from the same active ingredient as Jakafi, is being investigated for texture issues as the entire class of drugs faces scrutiny over heart and cancer…
The FDA is requiring new label warnings for Xeljanz and similar drugs, following a review which revealed links between increased risks of heart attacks, strokes, blood clots, and lymphomas, as…
Drugs in the same class as Xeljanz face increased scrutiny over concerns they may carry similar heart and cancer risks such as those suspected of plaguing the arthritis drug.
The FDA has delayed an expanded approval for the drug Jakafi, potentially due to concerns over heart and cancer risks linked to Pfizer's Xeljanz, a similar drug.
The bone marrow disease drug Jakafi may be linked to a rare and often deadly brain disease known as PML, according to a U.K. case study.